Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

To date, pharmacological treatments for mood and anxiety disorders and for drug
dependence show limited efficacy, leaving a large number of patients suffering severe and …

Background: Ayahuasca, a traditional Amazonian decoction with psychoactive properties, is
made from bark of the Banisteriopsis caapi vine (containing beta-carboline alkaloids) and …

Ayahuasca is a hallucinogenic botanical beverage originally used by indigenous
Amazonian tribes in religious ceremonies and therapeutic practices. While ethnobotanical …

Background The use of psychedelic treatments has shown very promising results in some
psychiatric and addictive disorders, but not all patients achieved a response. Aim The aim of …

Psychedelics are quite unique among drugs that impact the central nervous system, as a
single administration of a psychedelic can both rapidly alter subjective experience in …

Serotonergic hallucinogens produce alterations of perceptions, mood, and cognition, and
have anxiolytic, antidepressant, and antiaddictive properties. These drugs act as agonists of …

Ayahuasca ingestion modulates brain activity, neurotransmission, gene expression and
epigenetic regulation. N, N-Dimethyltryptamine (DMT, one of the alkaloids in Ayahuasca) …

The potent hallucinogen N, N-dimethyltryptamine (DMT) has garnered significant interest in
recent years due to its profound effects on consciousness and its therapeutic …

Recently, the anti-addictive potential of ayahuasca, a dimethyltryptamine (DMT)-and β-
carboline-rich hallucinogenic beverage traditionally used by indigenous groups of the …